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ABSTRACT

Production and Biocompatibility of Spider Silk Proteins in Goat Milk
by
Richard E. Decker Jr., Doctor of Philosophy
Utah State University, 2018

Major Professor: Dr. Randolph V. Lewis
Department: Biological Engineering
Due to its biocompatibility and impressive mechanical properties, spider silk has
great potential for a variety of commercial applications, from biomaterials to textiles.
Unfortunately, it is difficult and impractical to obtain native spider silk in sufficient
quantities to fully investigate these applications. In consideration of this problem,
recombinant spider silk proteins have been produced in a variety of hosts, including
microbes, plants, silkworms, and goats. While these recombinant proteins have potential
for meeting the demands associated with investigating spider silk’s impressive properties
more fully, each of the current production methods needs to be improved upon in one
way or another. Currently, goats produce the highest consistent yields of recombinant
proteins, but there is room for improvement in both production capacity and protein
length. The first focus of this dissertation was to establish a goat cell line designed to
increase the purity and quantity of recombinant proteins produced in goat milk by
incorporating a spider silk gene that encodes for a histidine-tagged protein into the goat
genome. Although multiple genomic integration techniques were investigated, the
PiggyBacTM Transposon Vector System was ultimately used to successfully establish a
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new “spider goat” cell line.
The second focus of this dissertation was to investigate the biocompatibility of
materials made from the current goat-derived recombinant spider silk proteins. Prior to
testing the biocompatibility of these proteins, a method was developed for destroying
endotoxins in the proteins that had been introduced during milk collection and
downstream processing. Two in vivo biocompatibility studies were conducted in rats by
implanting two different silk materials that had been treated using the endotoxin
destruction method established herein. In response to the low level of biocompatibility
discovered during these studies, another in vivo study was conducted using materials
made from goat-derived proteins that had been purified using reverse phase
chromatography. It was determined based on results from this final study that goatderived spider silk proteins are not biocompatible in their current state due to impurities
in the proteins and that further work is needed to improve the protein purity.
(103 Pages)
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PUBLIC ABSTRACT

Production and Biocompatibility of Spider Silk Proteins in Goat Milk
Richard E. Decker Jr.

Due to its strength, flexibility, and biocompatibility, spider silk is a highly
appealing material for applications in the medical field. Unfortunately, natural spider silk
is difficult to obtain in large quantities because spiders are territorial and cannibalistic,
making them impractical to farm. Synthetic spider silk proteins produced by transgenic
hosts such as bacteria and goats have made it possible to obtain the quantities of spider
silk needed to study it more fully and to investigate its potential uses. The spider silk
proteins produced in our laboratory do not have an optimal purification method to
remove all of the non-biocompatible contaminants and have not previously been tested
for their biocompatibility. The first focus of this dissertation was to create goat cells that
can be used to create new goats. These new goats will produce proteins that can be
purified more efficiently and more completely. The second focus of this dissertation was
to perform biocompatibility tests on goat-derived spider silk proteins. Prior to performing
any biocompatibility tests, a method was established for removing endotoxins – an
impurity that causes an immune response in the body – from the proteins. This work has
shed light on areas for improvement in the silk protein purification process and laid
groundwork for the production of new goat-derived proteins. These steps will help make
it possible for synthetic spider silk to progress further toward becoming a viable
biomaterial.
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CHAPTER 1
INTRODUCTION
Spider Silk
Spider silk’s biocompatibility and impressive mechanical properties make it an
ideal material for many applications. From wound healing among the ancient Greeks to
crosshairs in pre-World War II optical devices, spider silk has been used by mankind for
centuries1,2. Orb-weaving spider silk is of particular interest because orb-weavers produce
six different types of silk and one glue, composed of proteins ranging in size from 200350 kDa (Figure 1-1)3. Each of these silks is unique in its molecular structure, function,
and mechanical properties. The most studied spider silk is major ampullate silk, largely
due to its high tensile strength and toughness3. Major ampullate silk is made up of two
proteins, Major Ampullate Spidroin 1 (MaSp1) and Major Ampullate Spidroin 2
(MaSp2)4. Major ampullate silk is used in web construction and is also a lifeline for the
spider. It is often referred to as dragline silk because a spider will leave, or drag, a trail of
major ampullate silk when walking to catch itself if it falls. The extensibility and tensile
strength of dragline silk fibers prevent the spider from falling too far or stopping too
abruptly.
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Figure 1-1: There are six different types of spider silk: aciniform (yellow), cylindrical or
tubulliform (brown), flagelliform (green), major ampullate (red), minor ampullate
(purple), and pyriform or piriform (orange), as well as one protein-glue, aggregate (blue).
As shown (via color coding), each type of silk has a different use for the spider with
mechanical properties that are specific to their role in survival, prey capture and/or
reproduction5 (Image reprinted with permission. Credit: Patricia J. Wynne).
While these mechanical properties are essential for the life of the spider, they also
make spider silk a highly promising material for use in the biomedical field6–8 and for a
variety of other uses. Some of the proposed uses for spider silk include non-medical
applications like parachute cords, tire linings, and high-performance sportswear, as well
as medical applications such as replacement ligaments, tissue scaffolds, drug storage
matrices, and drug delivery systems9–11. Although spider silk holds great promise, natural
silk is very difficult and impractical to harvest because spiders are territorial and
cannibalistic. Lack of silk material makes it nearly impossible to investigate most of
silk’s potential uses, let alone create any products at a marketable scale.
To obtain spider silk proteins in the quantities required to study silk for its many
proposed applications, synthetic spider silk proteins are being produced in a variety of
transgenic hosts (Figure 1-2)7,12–16. There are hurdles involved with creating materials
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from recombinant silk proteins created in transgenic hosts, such as the difficulty of
spinning fibers from the proteins and the introduction of contaminants into the materials
during protein production and processing that can affect the biocompatibility of the
materials. In spite of these hurdles, there are advantages to producing silk proteins using
transgenic hosts beyond just increased quantities of protein. Another major advantage is
that materials made from recombinant spider silk proteins can be tailored through postproduction processing of the materials or genetic alterations to the proteins themselves to
have increased extensibility or increased strength, further increasing the potential
applications of spider silk.
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Figure 1-2. Brief history of recombinant spider silk protein production: (a) Production of
synthetic spider dragline silk protein in Pichia pastoris in 199613, (b) synthetic spider
dragline silk proteins and their production in Escherichia coli in 199717, (c) production of
spider silk protein in tobacco and potato in 200112, (d) spider silk fibers spun from
soluble recombinant silk produced in mammalian cells in 200218, (e) expression of
EGFP-spider dragline silk fusion protein in BmN cells and larvae of silkworm, which
showed that solubility is the primary limitation for the yield of spider silk protein, in
200719, (f) construct synthetic gene encoding artificial spider dragline silk protein and its
expression in the milk of transgenic mice in 200720, (g) transgenic silkworms (B. mori)
producing recombinant spider dragline silk in cocoons in 200921, (h) engineering
the Salmonella type III secretion system to export spider silk monomers in
200922, (i) native-sized recombinant spider silk protein produced for the first time in
metabolically engineered E. coli resulting in a Kevlar-strength fiber in 201023,
and (j) transgenic silkworms transformed with chimeric silkworm–spider silk genes
producing composite silk fibers with improved mechanical properties in 201224. The
organization of the important motifs in spider silk proteins, which is modified from
Hayashi et al.25 and Teule et al.14. The colored-squares indicate the modules contained in
each silk protein. The proteins are: MaSp1 and MaSp2, major ampullate spidroin 1 and 2
from Nephila clavipes; ADF-1, ADF-2, and ADF-3, minor ampullate, putative
cylindrical, and major ampullate, respectively, from Araneus diadematus25 (Reprinted
from Chung et al.7 with permission).
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Transgenic Hosts
Eukaryotic Cells
One potential method for producing recombinant silk proteins is through cultured
cells. Our group has shown that spider gland cells may produce silk proteins when in
culture, but because glandular cells do not proliferate we have been unable to
successfully establish a glandular cell line (unpublished data). Insect cells, which should
have similar biological and chemical properties to spider cells, have also been explored
for spider silk production. While there are a limited number of studies relating to spider
silk production in insect cells, spider silk-like proteins have been produced in both BmN
Bombyx mori (BmN) cells and Spodoptera frugiperda (Sf9) cells19,26. One of the reports
on silk proteins produced in BmN cells related sparse results, simply stating that the
proteins were only about 70 kDa and “probably occupied 5% of the total cell protein”19.
Vollrath et al. showed that silk could be produced in Sf9 cells that had the same chemical
properties as natural silk, but the resulting fibers were too fragile to be tested
mechanically26. While this might indicate that the proteins were not truly similar to those
produced by spiders, the fragility was more likely due to poor fiber spinning techniques
available at the time.
In 2002, Lazaris et al. successfully produced silk in cultured mammalian cells,
including bovine mammary epithelial cells and baby hamster kidney (BHK) cells18. Like
fibers produced from insect cell-derived proteins, the fibers produced from the protein
created by bovine and BHK cells were also brittle. It was suggested that this could be due
to a depletion of the aminoacyl-tRNA pool in vitro causing truncated proteins18, although,
similar to silk from insect cells, the brittleness of the fibers was more likely due to a lack
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knowledge regarding spinning synthetic spider silk fibers available at the time (and the
lack of proteins needed to improve that knowledge) leading to poor spinning methods.
Unfortunately, regardless of whether silk produced in insect or mammalian cells would
be similar to those in nature with more biomimetic spinning techniques, the cost
associated with producing proteins in a cell line is much too high to consider on a
commercial scale for a non-therapeutic protein.
Bacteria (E. coli)
Escherichia coli (E. coli) has been well studied and has a short doubling time,
making it an attractive host for producing high quantities of silk proteins. Because of this,
E. coli has been used to express multiple spider silk proteins17,27. In 2010, researchers
claimed to have produced silk proteins in E. coli that are similar in size to native silk
proteins23, but no group has been able to reproduce these results. Because protein size is
at least partially responsible for the strength of spider silk fibers, truncated proteins are
detrimental to the strength of the resultant materials23,28. One of the proposed causes of
the truncated proteins is that spider silk proteins are highly repetitive and contain large
amounts of glycine, alanine, and proline3,4,29. E. coli have a limited tRNA pool and,
therefore, do not produce enough of these amino acids to create full-length proteins and
still support regular cell function. Although increased work on silk production in E. coli
is leading to the production of larger proteins at increased quantities, other transgenic
systems, such as plants, silkworms, and goats, have been investigated to avoid or
minimize tRNA pool depletion issues.
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Plants
There have been some notable achievements in spider silk production using
plants. In theory, plants should be able to produce larger silk proteins without the addition
of any tRNAs. Scheller et al. were able to produce silk-like proteins in both potato and
tobacco plants in which there was no genetic instability caused by the recombination of
repetitive proteins, a problem seen in some other transgenic systems12,15. The silk proteins
comprised up to 2% (average >0.5%) of the total soluble protein when produced in the
endoplasmic reticulum (ER) 12. It is noteworthy that the silk proteins had a high resistance
to heat, which made them easier to extract and purify by removing smaller proteins12.
Proteins of up to 100 kDa were detectable in the plant tissue, which is comparable to, if
not better than, products from other transgenic systems, but still much smaller than the
natural protein size12.
Our group is investigating production of spider silk proteins in alfalfa. These
studies have led to transgenic plants that produce silk proteins predominately in their
leaves. Transgenic alfalfa would be one of the most cost-effective systems for producing
spider silk proteins for two major reasons: 1) alfalfa is a perennial plant, meaning
transgenic fields could be established and then grown year after year and 2) the plant
waste could potentially be used as feed for livestock or fuel for ethanol production, thus
boosting the economic value of the crop as a whole. In spite of the accomplishments in
developing plants that produce spider silk proteins and their great potential, the major
hurdle preventing the use of plants for spider silk production at a commercially viable
scale is the protein purification process. Using metal affinity chromatography, such as a
His-tag purification system, is problematic because it cannot be scaled to the level
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necessary to extract silk proteins on a large scale. Metal affinity chromatography is also
problematic for purification from plants because chlorophyll is a charged protein that is
extracted along with histidine-tagged silk proteins. Extracted chlorophyll leads to
contamination, damaged metal affinity media and equipment, and lower yields of silk.
While developing a method for extracting recombinant silk from alfalfa or other plants at
a large scale would lead to one of the most scalable and economically sustainable
methods for producing large quantities of spider silk proteins, purification from this
system remains a significant challenge.
Silkworms
Through the use of targeted genomic integration, our laboratory group has also
recently been able to create transgenic silkworms that produce up to 15% spider silk in
combination with their native silk. One major advantage to using silkworms to produce
spider silk is that they are a self-contained spinning apparatus, which removes the
complications associated with trying to spin spider silk fibers from recombinant proteins
with biomimetic equipment that will likely never be as good as natural spinning systems.
Although the data is unavailable due to patent filing concerns, the fibers produced by
transgenic silkworms have mechanical properties approaching those of native spider silk
fibers. In spite of the benefits of using silkworms to produce spider silk, there are still
some downfalls: 1) the silkworms still produce sericin, a protein glue that is
immunological, which must be removed via multiple treatment steps before the silk can
be used as a biomaterial, and 2) extensive processing of the fibers is required to make it
possible to create non-fiber materials. In both cases, the processing required can lead to a
reduction in the overall strength of the proteins.
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Goats
Following the work done by Lazaris et al. to produce spider silk in mammalian
cells30, Nexia Biotechnologies, in cooperation with Dr. Randy Lewis, created transgenic
goats that produce spider silk proteins in their milk (Nexia Biotechnologies, unpublished;
2002)31. Those goats’ offspring are currently the best system for producing large amounts
of transgenic spider silk proteins, albeit at a shorter size than native proteins (65 kDa). In
spite of their shorter size, the large quantity of available protein has enabled
improvements to be made in the spinning process, which has led to fibers that are
mechanically more similar to native fibers32, as well as the investigation of other silkbased materials such as thin films and hydrogels33,34.
Transgenic goats are ideal animals to work with for the production of spider silk
proteins in milk. Goats are relatively small, their waste is easy to dispose of, and they
produce a reasonably large amount of protein-rich milk. The spider silk genes are
heritable, so the herd size can be scaled up relatively easily through standard goat
breeding. Although scalable purification is a concern for using goat-derived silk proteins
for markets requiring excessive amounts of materials such as the textile industry, using
the proteins for medical applications is economically favorable given the lower amount of
silk that would be required and the high value of the materials compensating for more
costly production when compared to alfalfa or E. coli35. Also, the FDA has previously
approved the production of pharmaceuticals in goats’ milk36, so there is a standardized
pathway for FDA approval. Goats are, therefore, currently the optimal method for
obtaining transgenic silk for medical applications because they will allow for protein to
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be produced at high enough quantities in a relatively short period of time and in an FDA
approvable manner.
Dissertation Research Aims
Aim 1: Transgenic Goat Cell Line
To create the “spider goats” in use today, Nexia incorporated spider silk genes
into a modified version of the pBC1 Milk Expression Vector system (Invitrogen, no
longer commercially available). The pBC1 plasmid uses the goat β-casein promoter to
produce a protein of interest in a host’s milk. Not only is the pBC1 plasmid extremely
large (22 kb) and difficult to modify due to its multiple cloning site containing a single
restriction enzyme cut site, but it also utilizes random integration to incorporate its cargo
into the host genome. Although many random integration systems can be used to
effectively incorporate a gene of interest into a host, there are potential issues with
random integration, beyond the obvious problem of not knowing ahead of time where the
foreign gene will integrate into the host genome. It is possible that the gene of interest
will be incorporated such that it will interrupt an existing gene, thus silencing production
of a native protein, or that the gene of interest will be incorporated at a locus that will
generate lower protein yields. Since the creation of the original “spider goats,” there have
been advances in genome editing that have led to the development of techniques that are
superior to pBC1 for incorporating a foreign gene into a host genome. The first aim of
this dissertation was to explore some of these improved techniques of genomic editing in
order to establish a transgenic goat cell line to be used for somatic cell nuclear transfer to
create goats that will produce histidine-tagged proteins from a codon optimized silk gene.
Although this work is presented in Chapter 2 – CRISPR and PiggyBac Mediated
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Development of a Transgenic Goat Cell Line, some background on the targeted gene
editing techniques investigated is provided below.
TALENs
Researchers have known of transcription activator-like effectors (TALEs) for
decades, but the key to understanding their specificity was deciphered less than a decade
ago37. TALEs are produced by Xanthomonas bacteria and are composed of variable
regions that recognize specific DNA sequences38–40. Following the elucidation of their
specificity, TALEs became a major topic of interest. Cermak et al. developed a method to
engineer transcription activator-like effector nucleases (TALENs) by combining the
DNA fragments coding for naturally occurring TALEs with a mutated FokI
endonuclease39. These engineered TALENs can be designed to create double-stranded
breaks (DSBs) at nearly any region of the genome of nearly any host39–41. In 2012,
Carlson et al. successfully used TALENs to facilitate a gene knockout in livestock,
proving that engineered TALENs are a viable method for creating DSBs and genetic
manipulation in large mammals40. One potential drawback of using TALENs is that each
DSB requires a pair of TALEN proteins. This increases the load placed on the cells into
which the TALENs are transfected and can decrease the transfection efficiency,
especially if multiple cuts are needed. In spite of this, it has been shown that when two
TALENs are used in tandem the efficiency of gene modification was similar to that of the
predecessor to TALENs, Zinc Finger Nucleases (ZFNs), but without the unintended
chromosomal rearrangements that are a common side effect when using ZFNs40.
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CRISPRs
The newest site-specific gene editing tool employed in this project is clustered
regularly interspaced short palindromic repeats (CRISPRs). CRISPRs create CRISPRassociated (cas) proteins, which are RNA-guided nucleases that create targeted DSBs42.
The most commonly used cas is Cas9, which has been shown to function in many
different systems, including human cells43,44, rice45,46, hamsters47,48, and mice49.
Compared to other engineered site-specific nucleases such as zinc-finger nucleases and
TALENs, CRISPRs are quicker, easier, and less expensive to create, in that they only
require a standardized plasmid and a 17-22 bp double-stranded oligonucleotide matching
the target sequence. There have been concerns regarding off-target recognition and
cleavage by the CRISPR/Cas9 method due to the smaller size of the recognition sequence
leading to off-target recognition and non-specific cleavage43, but it has been shown that
using shorter recognition sequences actually decreases the frequency of off-target
cutting50. The low cost and ease of production, diverse targets and hosts, and high
efficiency of CRISPR/Cas9 make it one of the most promising gene editing systems
available. The impact the CRISPR/Cas9 system is having on research in biotechnology,
agriculture, and gene therapy and other medical applications, such as providing a
potential “cure” for HIV-151, is very impressive52.
Aim 2: Endotoxin Removal and Biocompatibility Studies
Although native spider silk is well known as a biocompatible material, synthetic
spider silk produced in our laboratory (both goat- and bacterially-derived) has not been
tested for its biocompatibility. To bring synthetic spider silk into the medical field,
biocompatibility tests are essential. Results of these tests can either be used to confirm
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biocompatibility or elucidate areas of improvement in protein purification and processing
to establish biocompatibility. As such, the second aim of this dissertation was to perform
biocompatibility tests on materials made of goat-derived spider silk proteins.
Aim 2-1: Endotoxin Removal
One major concern when preparing to test the biocompatibility of any biomaterial
is the presence of endotoxins. Endotoxins, also known as lipopolysaccharides (LPS), are
small, heat stable toxins present in gram-negative bacteria that are released during growth
and upon cell death. Endotoxins can illicit an immune response independent of the effects
of the biomaterial itself, thus producing confounding results in biocompatibility studies53.
Consequently, it is essential to ensure endotoxins are removed from or destroyed in any
biomaterial prior to investigating its biocompatibility. The most common methods for
endotoxin removal/destruction – dry heat (>180 °C) and caustic rinses (e.g. NaOH) –
cannot be used on most proteins, including spider silk, as they denature and/or leave
residual chemicals in the proteins53. In the case of spider silk, this is detrimental, as
denaturation of the proteins leads to the loss of mechanical properties and negates one of
the key reasons for using spider silk as a biomaterial. To avoid these issues, a method to
destroy endotoxin in synthetic spider silk protein, without compromising its mechanical
abilities, was developed and employed to prepare samples for in vivo biocompatibility
tests. This method and its effectiveness are presented in Chapter 3 – Method for the
Destruction of Endotoxin in Synthetic Spider Silk Proteins.
Aim 2-2: In vivo Biocompatibility Tests
Although in vitro tests were performed on our synthetic spider silk using Chinese
hamster ovary cells and BHK cells (unpublished data), these tests did not provide much
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useful information regarding the silk’s biocompatibility beyond demonstrating that the
silk does not appear to affect cell viability or have any cytological effects on the cells. To
obtain impactful data on the biocompatibility of goat-derived spider silk, in vivo tests
were conducted in rats using spider silk films and hydrogels that had been treated with
our newly developed method for endotoxin destruction (Chapter 3). The details and
results of those in vivo studies are presented in Chapter 4 – Investigation of the In Vivo
Biocompatibility of Goat-derived Spider Silk Protein. Chapter 4 also includes
information regarding an effort to redesign the processing and purification pathway of the
goat-derived silk proteins in an attempt to reduce the inflammatory response seen in our
initial studies that were likely caused by contaminants in the synthetic silk.
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CHAPTER 2
CRISPR AND PIGGYBAC MEDIATED DEVELOPMENT OF A TRANSGENIC
GOAT CELL LINE
Chapter Preface
This chapter presents work completed and problems encountered relating to
incorporating a spider silk protein gene into the goat and hamster genomes. Four methods
of incorporating the spider silk gene were employed: transcription activator-like effector
nucleases (TALENs), pBC1, clustered regularly interspaced palindromic repeats
(CRISPRs) and CRISPR associated protein 9 (Cas9), and PiggyBac. TALENs and
CRISPR/Cas9 were both used to produce targeted double-stranded breaks in the genome
and induce homology directed recombination (HDR). PiggyBac and pBC1 are both
random integration plasmid systems into which the spider silk gene was incorporated.
The pBC1 Milk Expression Vector (Invitrogen, K270-01), which utilizes the goat βcasein promoter to facilitate protein production in milk, is no longer commercially
available, but it was the original expression system used to create transgenic “spider
goats,” which is why its use was attempted early on in the project.
TALENs and pBC1 were used in the early stages of the project (first year, 20122013), but there were many difficulties associated with both systems, especially in
regards to determining whether either system had worked successfully. Although
repeated attempts were made to use the TALEN system to cleave the goat genome, no
success was observed. It is possible that this was due to the nature of the cleavage being
attempted – two cuts to remove a large portion of the genome (~11kb), requiring four
TALEN plasmids (two per cut). It is also possible that cleavage (TALENs) and
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incorporation (pBC1) was not detected due to low transfection, expression, and
incorporation efficiencies. This, combined with a lack of selection markers to promote
proliferation of successfully transfected/edited cells, would have made it nearly
impossible to detect positive results.
Because the CRISPR/Cas9 system was developed in 2013, soon after the start of
the project, the TALEN and pBC1 systems were abandoned in favor of this easier, less
expensive, higher efficiency method. In light of this, the TALEN and pBC1 work will not
be included in the following chapter, as it does not add any significant value to the work
attempted and completed. Regardless, the researchers would like to acknowledge that the
plasmid kit used for generation of TALENs in this project was a gift from Daniel Voytas
and Adam Bogdanove (Addgene kit # 1000000024)1.
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Introduction
Genetic manipulation of organisms by humans has been conducted for millennia,
from farmers selectively growing crops to breeders selectively breeding for particular
traits in animals. Although genetic work has been conducted in a laboratory setting for
nearly a century, much of this work has been conducted using random integration
methods – a gene of interest is “forced” into the genome at a random or semi-random
location. Using these random integration methods, the gene of interest is usually
incorporated at multiple loci within the genome that can be difficult, if not impossible, to
determine. Fortunately, genetic manipulation has become significantly more
“programmable” and consistent over the last two decades thanks to the discovery of
programmable nucleases such as zinc finger nucleases (ZFNs), transcription activatorlike effector nucleases (TALENs), and clustered regularly interspaced repeats (CRISPRs)
and CRISPR associated proteins (Cas), with Cas9 being the most widely used Cas2,3.
With the advent of these technologies, it has become possible to quickly, easily, and
precisely make modifications to the genome of many different organisms. The
applications for targeted genomic engineering range from studying diseases, particularly
genetic diseases, to the amplification or addition of specific traits in food crops such as
rice, to altering the genome of a mammal4–8.
One interesting example of genetic manipulation is the production of spider silk in
transgenic goats’ milk9. Spider silk, particularly major ampullate or dragline silk, has
gained a lot of interest as a potential biomaterial due to its strength and
biocompatibility10–12. Due to complications with farming spiders efficiently at a large
scale, synthetic spider silk has been investigated as a substitute for natural spider silk.

24

Although many hosts have been investigated to produce synthetic spider silk, such as
bacteria13,14, silkworms15, yeast16, and plants17, the most consistently high yields of larger
spider silk proteins are currently produced in transgenic goats. Unfortunately, the silkcoding genes have been randomly integrated into the goat genome using an outdated
system (pBC1) without provision for affinity chromatography. Because of this, it is
believed that the goats may not produce silk as efficiently as possible. It is also
speculated that the current protein purification process not only leads to a loss of protein,
but also increases the opportunity for contamination with endotoxin and other
environmental contaminants. To address these issues, we sought to integrate a spider silk
gene with a histidine tag at a targeted locus in the goat genome.
The main focus of this study was to replace one of the native milk protein coding
genes in the goat genome, specifically the αS2-casein gene, with a gene encoding one of
the two proteins that make up dragline silk, specifically major ampullate spidroin 1
(MaSp1)18. We theorized that incorporating the MaSp1 gene in the genome such that it
would be controlled using the native protein production, excretion, and packaging
systems of the goat would improve the quality and increase the quantity of the spider silk
protein being produced by the goat. To attempt this, the CRISPR/Cas9 system was
employed to induce multiple double-stranded breaks (DSB) in the regions of the genome
surrounding the αS2-casein locus in order to incorporate the MaSp1 gene into the genome
via homology directed recombination (HDR).
Although fully removing and replacing an existing gene via targeted DSB
production and subsequent HDR was the ideal situation in this project, there are many
complexities associated with the work that make the process extremely difficult to
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complete. Therefore, it was concluded that, even if full gene replacement was not
possible, randomly incorporating a MaSp1 gene with a histidine tag would still have an
important impact on improving the overall amount and purity level of silk protein
obtained. In light of this, the PiggyBacTM Transposon Vector System, a semi-random
integration system, was used as a contingency plan for integrating silk genes with a
histidine tag.
Due to some issues early on with knocking the silk into the goat genome, we also
attempted to knock the same silk construct into the Syrian hamster (Mesocricetus
auratus) genome as a pilot study to determine whether our method (using CRISPR/Cas9
and HDR to incorporate a large gene) would be feasible before continuing the work in the
goat genome. Hamsters were chosen for their shorter gestational period and available
secondary cell line – baby hamster kidney (BHK) cells. The BHK cell line is very hardy
and easy to work with. Also, CRISPR gene editing in hamsters has been successfully
accomplished by others previously6,7,19.
Herein we present the hurdles, failures, and successes associated with integrating
a histidine-tagged spider silk gene into the goat genome.
Materials and Methods
CRISPR/Cas9
CRISPR/Cas9 constructs (referred to herein as CRISPRs) were created by
incorporating CRISPR guide RNA sequences (gRNAs) into the pX330-U6Chimeric_BB-CBh-hSpCas9 plasmid backbone, referred to herein simply as pX330.
pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang (Addgene plasmid #
42230)20. Guide RNAs were selected using the CRISPR Design tool at crispr.mit.edu
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with NGG as the protospacer adjacent motif (PAM) sequence. Guides of 17-20 bp were
prioritized. Potential off-target loci were determined by running the gRNAs in BLAST
against the goat or hamster genome to find sites that matched the seed sequence (first ~10
bp) and included the PAM sequence. Hamster off-target scores were also assessed via the
Benchling CRISPR design wizard tool. Based on these criteria, no off-target sites were
predicted.
The efficiency of each CRISPR was determined using the GeneArt Genomic
Cleavage Detection Kit (Life Technologies A24372). CRISPRs determined to have the
highest efficiency were also tested together in pairs to determine whether their efficiency
would persist when co-transfected. Based on the results of these efficiency tests, final
gRNAs were selected – the highest efficiency gRNA sequences are shown in Table 2-1.

Table 2-1. Highest efficiency gRNAs incorporated into the pX330 plasmid to create
CRISPR constructs. Duplexes of these sequences were created by IDTDNA with “sticky
end” overhangs (not shown) to facilitate incorporation into pX330.
Target
Genome
Goat

Hamster

Name

Sequence (5’ – 3’)

CRISPR 2
CRISPR 3
CRISPR 8
CRISPR U2
CRISPR U5
CRISPR D1

TCTTTGATTATAGGTTTC
GAAACCTATAATCAAAGA
GTCTTAGGTTGAGTCCA
For distal end of gene
GGCTTGAGTATCTCATTCTGG
AACTATTTAGCATTAACACG
For NHEJ work
GTGATTTAACTGATCAACTTGG For distal end of gene

Notes

PiggyBac Transposon
The PiggyBacTM Transposon Vector System (System Biosiences, PB513B-1)
(referred to herein as PiggyBac), a semi-random integration method, was also used to
incorporate a spider silk gene into the goat genome. In order to facilitate silk production
in milk, the goat β-casein promoter was incorporated into PiggyBac along with the spider
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silk gene. A Neomycin resistance cassette (neo cassette) was also incorporated into
PiggyBac to allow for cell selection. Separate regulatory elements (promoter and stop
codon) were incorporated for the neo cassette. A plasmid map of the final PiggyBac
construct is shown in Figure 2-1.

Figure 2-1. Plasmid map of final PiggyBac construct with incorporated promoter, silk
coding sequence (MaSp1 (16x)), histidine tag, and neomycin resistance gene.

Silk Sequences and Homology Arms
MaSp1 and MaSp2 silk sequences used in this project were 16x repeats of
sequences created by LifeTechnologies specifically for our research group. Each 16x
repeat is 2046 bp long and encodes for an approximately 74 kDa protein. For pBC1 and
PiggyBac studies, silk sequences were cloned into a custom designed insert containing a
Kozak Consensus Sequence and milk secretion signaling sequence. For targeted
integration studies, silk sequences were cloned between two homology arms
(approximately 500 bp each) matching the flanking regions of the TALEN or CRISPR
target sites in either the goat αS2-casein or hamster β-casein genes to encourage silk
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integration via homology directed repair (HDR). Primers for the production of these
homology arms are shown in Table 2-2.

Table 2-2. Primers used for PCR and homology arm production.
Category
Genomic
Integration
Check

Name
Goat Silk Up F
Goat MaSp1 Up R
Goat UF3
Goat UR4
Ham Silk Int Up 2 F
Hamster BUF1
Hamster BUR1
MaSp1 Ham Check
MaSp2 Ham Check
MaSp1 F1
MaSp1 R3
Hamster
Ham Arms UF
Homology Ham Arms UR
Arm
Ham Arms DF
Production Ham Arms DR
Ham HA2F
Ham HA2R
Goat
New Goat HA DF
Homology New Goat HA DR
Arm
New Goat HA UF
Production New Goat HA UR

Sequence (5’ to 3’)
GGGAGGCAGGCTTCATGTT
CCTGCACCACCGGTCATATG
GCCCAAATGAGCCTCCAC
TCTGTGACTCTCCTGAACTTT
GGTAGCCCATGGAGGAGTCTTTAGAC
AGGAGGCAGAGTATAGTTTGAC
GGATATGCTGAGTGATTCCTTTTG
CCACCGGTCATATGGCCG
GGACCGGTCATATGGCCG
TAGCCAGGGTGCCGGTCG
CCCTCCCAGACCACCCC
CAGCATACATCCAAAAGGCCAAAA
AATCCGGATGCAAAAGCAAGTGCCAC
AATCCGGAAAGGTCTAAGAGGATTTCCAGG
GAAGTCACGACCCACATGTTG
AATCCGGATGTCCAAAGGGAAATTCAGTGG
CTTCCCTCACTGCTGGAAATG
AATCCGGATGAAGATGGACAAAAATACCACTTC
TTGTTGCTCTTTAGTCTCTCAGTCGTG
GCATTTCTGATGATTCTCCACAAG
TTTCCGGATGCAAGGGCAACGGCC

Cell Culture
For all goat studies, goat fetal fibroblast (gFF) cells, provided by Dr. Irina
Polejaeva’s research group at Utah State University, were used. For all hamster studies,
BHK cells, provided by Zhongde Wang’s research group at Utah State University, were
used. All cells were cultured in high glucose Dulbecco’s Modified Eagle Media (DMEM)
(VWR VWRL0101-0500) with 10% (v/v) Fetal Bovine Serum (FBS) (GE Healthcare
SH30071.03) and 1% (v/v) penicillin/streptomycin (Life Technologies 15140-122); nonessential amino acids (NEAA) were also added to a final concentration of 5% (v/v) for
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BHK cells. Cells were grown with 5% CO2 at 37 °C, with regular passaging.
Cryopreserved cells were stored in complete media with an additional 10% FBS and 10%
DMSO.
Transfection and Cell Selection
All transfections were conducted using the 4D-NucleofectorTM X Unit (Lonza
AAF-1002X). For gFF cells, Lonza’s AmaxaTM P3 Primary Cell 4D-NucleofectorTM X
Kit was used (Lonza V4XP-3024). For BHK cells, Lonza’s AmaxaTM SE Cell Line 4DNucleofectorTM X Kit L was used (Lonza V4XC-1024). Based on preliminary cell
viability and transfection efficiency experiments (data not shown) the EO-114 program
was used for gFF cells. The CA-137 program was used for BHK cells as recommended
on Lonza’s website. Due to variance in cell viability levels post-transfection, the number
of cells used between gFF and BHK transfections varied. Generally, 0.5x106 – 0.75x106
gFF cells were used and 0.3x106 BHK cells were used.
For PiggyBac experiments, a PiggyBac vector expressing green fluorescent
protein (GFP) was used as both a positive transfection control and a negative Neomycin
selection control. A PiggyBac vector containing a neo cassette was transfected as a
positive antibiotic selection control. Non-transfected cells were plated as a negative
antibiotic selection control. Cell selection was achieved by adding 900 µg/mL G418
Sulfate (VWR 97063-060) to the DMEM media starting at 48 hours post-transfection.
Transfected cells were not harvested until complete cell death in negative control wells
(typically ≥12 days).
Some cells were diluted and plated in a 96-well plate at ~200 cells/well to
establish single cell colonies. Remaining cells were plated in 6-well plates. Cells grown
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in 96-well plates with the highest probability of being single cell colonies (chosen based
on visual inspection) were transferred to 12-well plates when they reached 50%
confluence. Cells grown in 12-well plates were then harvested for analysis and
cryopreservation at 50% confluence. Cells grown in 6-well plates were harvested at
>90% confluence for analysis and cryopreservation.
Genomic DNA Extraction and PCR
Following transfection and cell selection, genomic DNA (gDNA) was extracted
from cells using the Qiagen QIAamp DNA Mini Kit (Qiagen 51304). Genomic DNA was
then evaluated via PCR using custom primers to detect for genetic changes in the form of
base pair insertions or deletions (indels) in the case of CRISPR evaluation studies or to
check for silk integration. Primers used in these PCRs are listed in Table 2-2. PCR bands
were extracted using Promega’s Wizard SV Gel and PCR Clean-Up System (Promega
A9281). Samples were then sequenced via the Sanger method.
Results and Discussion
CRISPRs in Goats, Part I
Initially, there were concerns that the CRISPR/Cas9 system would not work as we
were hoping, specifically to knockout and replace the αS2-casein gene. Because many of
the common cleavage detection kits in use now were not available during the initial
stages of the project, the efficiency of the CRISPRs being used had not been properly
evaluated. In spite of this, we attempted to incorporate spider silk anyway and then
focused on looking for silk incorporation to determine whether the CRISPR and HDR
method had worked. Unfortunately, this was not an ideal process to determine whether
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the CRISPRs were working effectively, as it was dependent on the success of the silk
integration. After numerous attempts to incorporate silk using a dual cutting
CRISPR/Cas9 strategy, it was determined that it would be beneficial to conduct a proof
of concept study in a hamster model.
CRISPRs in Hamsters
The CRISPR gRNAs used in hamster work were designed around the β-casein
gene – the only known milk protein gene produced in hamster milk – and the CRISPRs
with the highest cutting efficiency were selected. Genomic DNA of BHK cells
transfected with CRISPRs targeting both ends of the β-casein gene was extracted 72
hours post-transfection. Analysis of the gDNA indicated that both CRISPRs were cutting
when co-transfected. BHK cells were then transfected with CRISPRs and the plasmid
containing homology arms and the spider silk gene. PCR analysis performed on the
gDNA of these cells (also extracted 72 hours post-transfection) did not indicate
successful incorporation of the spider silk gene. Because multiple iterations of the same
experiment yielded the same results, CRISPRs and homology arms targeting/matching
the flanking regions of the start codon and secretion signal of the β-casein gene were
selected. Although HDR was the preferential repair mechanism for this study, the new
“upstream” CRISPR was selected such that it would create a double-stranded break
(DSB) in the middle of the homologous region of the genome and donor DNA, thus
facilitating Obligate Ligation-Gated Recombination (ObLiGaRe), a method for sitespecific gene insertions described by Maresca et al.21. Briefly, ObLiGaRe takes
advantage of the NHEJ repair mechanism to ligate exogenous DNA into a specific locus
in the genome by using a target specific genomic editing tool that recognizes both the
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donor DNA and the target site in the genome21. The new CRISPRs designed to induce
ObLiGaRe were evaluated for efficiency, and then co-transfected with the homology
arm/silk construct. Genomic DNA was extracted after 72 hours and subjected to PCR
analysis and subsequent sequencing. Both analyses showed that the CRISPRs had
successfully produced indels, with the strongest sequence detected via sequencing
showing spider silk gene integration (Figures 2-2 and 2-3). It is of note that the precise
integration point of the 3’ end of the gene could not be determined via PCR regardless of
the primer pairs used. Due to the impracticality of producing “spider hamsters,” these
results were deemed sufficient to validate the feasibility of creating new spider goats
using the CRISPR/Cas9 system (and to establish the skills of this researcher).
Consequently, neither a transgenic cell line nor transgenic hamster pups were created.

Figure 2-2. Gel electrophoresis analysis of PCR run on BHK gDNA. Primer pairs: (S1 or
S2) Ham Silk Int Up 2F + MaSp1 (or MaSp2) Ham Check; (B) BUF1 + BUR1. Gel 1 –
lane 2: BHK gDNA negative control (S1); lanes 3-6: cells transfected with MaSp1 (S1);
lanes 7-8: MaSp1 plasmids (not gDNA) (S1); lane 9-14: DNA negative controls (same as
3-8, but no primers); lane 15: primer negative control (S1, no DNA). Gel 2 – lane 2: BHK
gDNA negative control (S2); lanes 3-4: cells transfected with MaSp2 (S2); lane 5:
MaSp2 plasmid (not gDNA) (S1); lane 6-8: DNA negative controls (same as 3-5, but no
primers); lane 9: PCR positive control, BHK gDNA (B); lane 10: negative controls (no
DNA or primers); lane 11: negative primer control (S2). White arrows indicate bands
representing silk integration. Ladder: Thermo Scientific GeneRulerTM 1kb Plus DNA
Ladder.
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Figure 2-3. (Top) Electropherogram produced by sequencing a PCR run on gDNA
extracted from post-transfected BHK cells. Blue box and arrow indicate CRISPR/Cas9
target and cut site, respectively. Red box highlights spider silk sequence. (Bottom)
BLAST® Alignment of expected sequence (Query) and strongest signal from sequencing
(Sbjct).
CRISPRs in Goats, Part II
Following the success with BHK cells, CRISPR/Cas9 work was continued on gFF
cells. The CRISPRs used previously were re-evaluated and changed as needed to improve
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targeting efficiency in the goat genome. Similar to the hamster project, new CRISPRs
and homology arms were also created for the flanking regions of the start codon and
secretion signal of the αs2-casein gene, as opposed to the entire gene. Although the
CRISPR/Cas9 constructs consistently showed reasonable cutting efficiencies, spider silk
could never be detected as having been incorporated into the genome. It is speculated that
the silk could have been incorporated with the aid of selection pressure, but this avenue
was not explored during the course of this project when using the CRISPR/Cas9 and
HDR method. Another possibility for the lack of success in editing the goat genome is the
recently discovered phenomenon in which the CRISPR/Cas9 complex did not detach
from the site where it created a DSB, preventing cellular repair mechanisms from
working properly22. It is also worth noting that the ObLiGaRe technique used to
incorporate silk into the hamster genome was not investigated in goats due to concerns
with the gRNAs targeting the αs2-casein promoter region of the genome and the
homology arms leading to indel creation in the promoter and upsetting the potential for
protein production.
PiggyBac
The silk-containing PiggyBac vector, having been modified with a neo cassette
and the goat β-casein promoter (Figure 2-1), was transfected into gFF cells. Following
transfection (72 hours), GFP could be seen in >90% of the control cells under
fluorescence microscopy. Genomic DNA was extracted from Neomycin selected cells
14-17 days post-transfection (depending on transfection batch and complete cell death in
negative control wells) and analyzed via PCR for silk integration. As shown in Figure 24, all gDNA batches showed positive results for silk integration. These results, which
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were confirmed via Sanger sequencing (Figure 2-5), indicated that both mixed population
and single cell derived (or nearly single cell derived) cell lines containing the gene coding
for the MaSp1 spider silk protein have been established.

Figure 2-4. Gel electrophoresis analysis of PCR run on gDNA extracted from gFF cells.
Lanes 1-8 and 10-15: PCR on cells transfected with Piggy+MaSp1; lanes 16 and 17: PCR
on cells transfected with empty PiggyBac (negative integration control); lanes 19 and 20:
PCR on wild type gFF cells (positive PCR control, secondary negative integration
control); lanes 21 and 22: integration positive control; lanes 23 and 24: negative PCR
controls (no gDNA). PCR reactions in lanes 1, 3, 5, 7, 10, 12, 14, 16, 19, 21, and 23 were
all run with primer pair MaSp1 F1 and MaSp1 R3; all other PCR lanes were run with the
UF2 and UR3 primer pair. White arrows indicate bands representing MaSp1 integration.
Ladder: Thermo Scientific GeneRulerTM 1kb Plus DNA Ladder.
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Figure 2-5. BLAST® alignment comparison of expected sequence (Query) and sequencing
results (Sbjct) for MaSp1 incorporation into the goat genome via PiggyBac.

Future Work
The most immediate future work will be to use the transgenic gFF cells for
somatic cell nuclear transfer during the goat breeding season. Any kids produced from
these cells can be tested for transgenesis. Kids testing positive can then be milked and
silk protein can be extracted from the milk using affinity chromatography. The protein
can then be tested and compared to current goat-derived silk proteins.
Because it is assumed that the biggest problem with introducing spider silk into
the goat genome using the CRISPR/Cas9 system is the ability to select for positively
transfected cells, we believe that it might still be possible to use the CRISPR/Cas9 system
along with HDR or NHEJ to incorporate a spider silk gene into the goat genome at a
targeted location, but further modifications to the protein coding sequence would be
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necessary, i.e. incorporation of a selection marker. One possibility would be to include a
strong GFP marker with the silk protein gene, as this could allow for identification of
successful genomic integration as well as fluorescence activated cell sorting (FACS) to
obtain only transgenic cells. Initially, FACS was attempted on gFF cells, as the pX330
backbone vector used in these experiments contains a GFP marker, but the fluorescence
was not strong enough. Also, the presence of GFP in this case would not have indicated
successful genomic integration, merely successful transfection, so FACS would not have
been effective. By incorporating a stronger GFP coding cassette with the silk, the
possibility of successful FACS would increase significantly, which would facilitate the
establishment of a cell line with targeted silk integration.
Another possible selection method could be the incorporation of an antibioticresistance cassette into the silk/homology arm construct. It would be necessary to ensure
that the antibiotic-resistance cassette was controlled with its own regulatory elements,
similar to how the PiggyBac work was done, so the resistance gene would not be
produced as part of the silk. Otherwise, the spider silk would include an antibioticresistance gene, which could cause significant problems when considering medical
applications of the spider silk. The antibiotic-selection gene could also interfere with how
the silk performed mechanically if it were to be produced with the silk. In spite of these
concerns, with proper precautions antibiotic selection is a feasible approach to obtaining
gFF cells with integrated spider silk.
One concern with this project regardless of the integration technique is the size of
the resultant silk proteins. The mechanical properties of spider silk are dependent on the
length of the silk proteins – the longer the protein, the stronger the material23,24. Full
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length silk proteins range from 200 to 350 kDa12,25, while the silk proteins produced as a
result of this project will only be ~74 kDa. Although these proteins are not as long as we
would like, they are comparable to the goat-derived proteins currently in use. Because of
this, they can provide sufficient data for comparison between the current goat production
system and the modified system established through this work. If the results of these
comparisons are in favor of the new spider goats’ proteins, larger silk-coding genes can
be incorporated using the same methodology.

Conclusion
Although there is still work to be done, it is possible to create transgenic goat fetal
fibroblasts with genes coding for histidine-tagged MaSp1 spider silk protein using the
PiggyBacTM Transposon Vector System. These gFF cells will make it possible to create
new and improved “spider goats” that will make proteins that are significantly easier to
purify. This is an important step forward in the production of spider silk proteins for
medical applications in that it may allow for the collection of larger volumes of protein at
higher purity levels.
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CHAPTER 3
METHOD FOR THE DESTRUCTION OF ENDOTOXIN IN SYNTHETIC
SPIDER SILK PROTEINS1

Abstract

Although synthetic spider silk has impressive potential as a biomaterial,
endotoxin contamination of the spider silk proteins is a concern, regardless of the
production method. The purpose of this research was to establish a standardized method
to either remove or destroy the endotoxins present in synthetic spider silk proteins, such
that the endotoxin level was consistently equal to or less than 0.25 EU/mL, the FDA limit
for similar implant materials. Although dry heat is generally the preferred method for
endotoxin destruction, heating the silk proteins to the necessary temperatures led to
compromised mechanical properties in the resultant materials. In light of this, other
endotoxin destruction methods were investigated, including caustic rinses and
autoclaving. It was found that autoclaving synthetic spider silk protein dopes three times
in a row consistently decreased the endotoxin level 10-20 fold, achieving levels at or
below the desired level of 0.25 EU/mL. Products made from triple autoclaved silk dopes
maintained mechanical properties comparable to products from untreated dopes while
still maintaining low endotoxin levels. Triple autoclaving is an effective and scalable
method for preparing synthetic spider silk proteins with endotoxin levels sufficiently low
for use as biomaterials without compromising the mechanical properties of the materials.

1

This chapter was published in Scientific Reports and was co-authored by Thomas I. Harris, Dylan R.
Memmott, Christopher J. Peterson, Randolph V. Lewis, and Justin A. Jones.
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Introduction
The biocompatibility and mechanical properties of spider dragline silk set it apart
from most synthetic and natural materials as an ideal biomaterial. Dragline silk is made
up of two proteins, MaSp1 and MaSp21,2, whose structures make the resultant fibers
strong, extensible, and flexible.3 With synthetic spider silk proteins, these properties can
be harnessed into a variety of materials in addition to fibers, such as films, coatings, gels,
and adhesives4,5. Synthetic spider silk materials (including fibers) can also be tailored to
have increased strength and/or flexibility through mixing different ratios of the dragline
proteins. Due to its versatility, synthetic spider silk has great potential for a variety of
biomedical applications.
Although native spider silk is generally accepted as biocompatible6,7, it is difficult
to obtain in large quantities because spiders can only produce a limited amount of silk in
a day and cannot be farmed efficiently due to their territorial and cannibalistic nature. In
response to these issues, synthetic spider silk proteins have been produced in a variety of
hosts8,9, including yeast10, bacteria11,12, silkworms13,14, tobacco plants15, and goats16.
While each of these expression systems has advantages and disadvantages for producing
spider silk proteins, all are subject to contamination with environmental pyrogens,
especially endotoxins, during production and processing.
Pyrogens are substances that produce a fever that can quickly become
dangerously high. Endotoxins, one of the most prevalent pyrogens, are surface
lipopolysaccharides (LPS) released from gram-negative bacteria that are heat stable to
high temperatures17. As with all pyrogens, if endotoxins are present at high enough
levels, they will induce a fever18. Because of this, endotoxin level testing and subsequent
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removal or destruction is required for any implantable biomaterial19,20. Although
endotoxins are produced by gram-negative bacteria, they can be found in most
environments, particularly on a goat farm and in a laboratory environment21.
The most common method for pyrogen destruction (depyrogenation) of materials
such as packaging and medical devices is dry heat. Materials to be depyrogenated are
treated at 250 °C for ≥30 min17,22. The temperature can be adjusted, but it cannot be lower
than 180 °C, and at that temperature the samples must be treated for ≥3 hours22.
Unfortunately, most proteins and other polymers cannot withstand these high
temperatures. Although triple autoclaving has been proposed as a potential method for
removing endotoxin, the effectiveness of this and other alternative methods of
depyrogenation, including caustic rinses, is often debated17.
Common methods for removing endotoxin from solutions, such as size-exclusion
or ion-exchange chromatography, are effective for medical injectables and microbialproduced bioproducts such as small (<100 kDa), soluble proteins. Although spider silk
can be solubilized under specific conditions, it is likely to solidify as the conditions
change during the endotoxin removal processes. Ion-exchange chromatography often
leads to an increase in salt concentrations, which are detrimental to the formation of
spider silk materials23, and would require additional washing steps for the silk proteins.
Arguably the most significant problem with these methods of endotoxin removal is that
they are most effective on smaller soluble proteins. The mechanical properties of spider
silk materials are highly dependent on the size of the protein – larger (>100 kDa) is
better15,24,25. Due to these issues, common methods for removing endotoxins cannot be
used on silk proteins.
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In light of this, a method to destroy or remove endotoxins from synthetic spider
silk (or the materials produced from them) is needed to produce biocompatible and
implantable materials. To our knowledge, there is no such method that has been reported
in literature. To remedy this, we sought to determine the best method to either remove or
destroy endotoxins present in synthetic spider silk proteins and synthetic spider silk
protein-based materials while maintaining the valuable mechanical properties of the
spider silk.

Results and Discussion
As can be seen in Table 3-1, it is possible to decrease the endotoxin levels of
synthetic spider silk protein by autoclaving three times. Dry heating also decreased the
endotoxin level (data not shown), but even at the lowest acceptable treatment temperature
of 180 °C the recombinant spider silk’s mechanical properties were compromised.
Protein treated with dry heat made very poor films that could not be tested because they
broke when handled. Similarly, dry heated fibers also became very brittle. This decrease
in mechanical properties is likely due to the extreme dehydration and resultant
degradation of the spider silk that occurs at high temperatures and/or pressures23. The dry
heated protein also had significant discoloration (brownish-yellow or black), indicating
that it had been charred. Due to the detrimental effects of dry heating on the mechanical
properties of the samples, the dry heat treatment method was discarded. In contrast, the
autoclaved protein samples maintained their color and the resultant films had mechanical
properties similar to films made from untreated proteins (Table 3-2). It is also of interest
that films maintained decreased endotoxin levels when they were made on endotoxin-free
polydimethylsiloxane (PDMS) molds, but not when made on untreated PDMS molds
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(Table A1-1, sample 15). This further confirms that autoclaving destroys the endotoxin in
the silk proteins.
Table 3-1. Combined average endotoxin levels of all goat-derived spider silk proteins
and films before and after treatments. Individual sample group averages are shown in
Table A1-1. The R2 of the endotoxin analysis kit standard curve was ≥0.989 for all
experiments. Silk samples below 0.25 EU/mL are in bold. Standard deviations were
calculated using STDEV.P in Microsoft Excel.
Sample Type

Treatment

Results (EU/mL)

n

Protein Powder
Film
Film
Protein Powder
Protein Powder
Films
Films

None
NaOH rinse + H20 rinse
NaOH rinse + H20 rinse
Doping
Doping + Autoclaving x3
Doping + Film
Doping + Autoclaving 3x + Film

5.92 ± 0.07
2.08 ± 0.11
4.05 ± 0.42
3.20 ± 1.71
0.17 ± 0.09
0.81 ± 0.36
0.18 ± 0.07

2
2
2
16
14
4
11

Only protein powder, dopes (protein solubilized in water using microwave
irradiation to generate high heat and pressure; for details see Methods), and fibers were
treated via autoclaving because films deformed (melted) when autoclaved and could not
be tested. All film samples presented here were made from autoclaved dopes.
Although triple autoclaving did not cause fibers to become as brittle as dry heated
fibers, which broke when handled, the autoclaved fibers still had a significant drop in
mechanical properties. It was possible to handle most of the autoclaved fibers to prepare
them for mechanical testing, but the samples broke before any meaningful data could be
gathered during testing. Some samples were autoclaved immersed in water to test
whether dehydration was the sole cause of the increased fragility, but the result was the
same, indicating that the issue could be due to the combination of high temperature and
high pressure over time.
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Because early tests indicated that it would be necessary to eliminate endotoxins in
synthetic spider silk fibers (data not shown), dry heat and autoclaving treatments were
investigated. While it was found that autoclaving did decrease the endotoxin level in most
fiber samples, the results were not as consistent as those of dopes and film samples.
Table 3-2. Data from tensile tests on films made from triple autoclaved and untreated
synthetic spider silk dopes. Groups A, B, and C were made from different dopes of the
same protein; all received the same 3x autoclave treatment. All MaSp1 sample groups
were created from dopes made from the same goat-derived protein stock, but at different
times. MaSp2 samples were made from dopes of bacterially-derived protein. Standard
deviations were calculated using STDEV.P in Microsoft Excel.

Sample

Unstretched
MaSp1

Unstretched
Resolubilized
MaSp1
Unstretched
MaSp2
Stretched
MaSp2

Group

Average
Maximum
Stress
(MPa)

Average
Maximum
Strain (%)

Average
Maximum
Toughness
(MJ/m3)

n

Untreated

39.1 ± 21.2

1.8 ± 0.2

0.33 ± 0.2

6

A

41.7 ± 3.8

1.7 ± 0.3

0.32 ± 0.08

4

B

21.5 ± 7.1

1.6 ± 0.1

0.16 ± 0.04

2

C

52.3 ± 6.1

1.9 ± 0.2

0.45 ± 0.08

4

Not Centrifuged 73.9 ± 15.2

2.3 ± 0.3

0.82 ± 0.31

5

Centrifuged

45.9 ± 10.2

2 ± 0.3

0.47 ± 0.14

3

Untreated

189.1 ± 25

3.2 ± 0.4

3.06 ± 0.54

4

Autoclaved

134.1 ± 29

2.5 ± 0.6

1.69 ± 0.82

4

Untreated

104.7 ± 32.3

57 ± 5

50.65 ± 10.55

4

Autoclaved

79.2 ± 17.8

23 ± 11

15.24 ± 6.63

3

Unlike fibers, the mechanical properties of silk films were consistent between
films made from untreated dopes and autoclaved dopes (Table 3-2). Generally, stretching
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films increases the mechanical properties of spider silk films5. In this case, the average
ultimate tensile stress of the films was decreased due to stretching, but the strain was
greatly increased. It is possible that this was due to the degree of stretching used or due to
the stretched samples being composed completely of MaSp2. Native spider dragline silk
and many synthetic spider silk films contain at least some MaSp1, which contains
additional strength producing crystalline motifs3. Although autoclaving has been shown
to affect the structure of silkworm silk26,27, Hedhammer et al. showed that one round of
autoclaving spider silk did not affect the structure of the silk28. It is also very likely that
any structural changes that may have occurred due to autoclaving are “reset” when the
protein is redoped after autoclaving. This lack of structural difference not only explains
the similar mechanical properties of the treated and untreated films, but is also beneficial
when comparing treated and untreated proteins, as they are more analogous to each other.
The resolubilization “treatment” referenced in Table 3-2 consisted of triple
autoclaving protein powder in water, then, following autoclaving, centrifuging the
protein-water mixture, removing the water, and freezing the pellet, or simply freezing the
autoclaved protein-water mixture. Both samples were then lyophilized and redoped. This
was done to determine whether it would be possible to create stocks of endotoxin-free
protein and whether it was better to remove the water previous to freezing and subsequent
lyophilization or not. As can be seen in Table 3-2, the films made from dopes that
received the resolubilization treatment had mechanical properties similar to films made
from freshly treated dopes. This indicates that it is possible to create stocks of endotoxinfree synthetic spider silk that can be used at future times to make endotoxin-free
materials. Unfortunately, the practicality of maintaining an endotoxin-free “common
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stock” in a laboratory setting is that the stock will not stay endotoxin-free for very long.
However, in certain conditions, such as a clean room, good laboratory practice, or good
manufacturing practice, an endotoxin-free stock may be very practical and beneficial.
Based on the “Not Centrifuged” and “Centrifuged” samples, autoclaving, freezing, and
lyophilizing without removing the water from the dope may give better mechanical
properties than centrifuging the dope and removing the water before freezing and
lyophilizing.
Most of the samples tested in this experiment were from goat-derived spider silk
protein. Ideally, synthetic spider silk will be produced predominately in E. coli.
Hedhammar et al. were able to create fibers from small recombinant spider silk proteins
produced in E. coli with low pyrogenicity by treating the bacteria with a combination of
Tris, Ca2+, and EDTA before cell lysis and subsequent silk extraction28. While this
method of endotoxin removal is beneficial for a bacterial production system, it is still
difficult to produce native size spider silk proteins in bacteria. Because of this, there is
great benefit in developing a method of endotoxin removal/destruction that can be
applied to synthetic silk proteins regardless of the production system. In this study, a
batch of bacterially-derived spider silk protein was treated by triple autoclaving. Results
indicate that the treatment method also effectively removes endotoxin in the bacteriallyderived silk (Table 3-3). It is notable that autoclaving silk proteins is more easily scalable
and likely less expensive than the endotoxin removal method developed by Hedhammar
et al., as autoclaving does not require any reagents or extra purification steps.
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Table 3-3. Endotoxin levels of bacterially-derived protein and subsequent films that were
either treated with autoclaving or untreated. Empty vials were vortexed with endotoxinfree water in them and the water was tested. The R2 of the standard curve was 0.9913 for
all tests. All samples had n=2 except B7, which had n=1 due to contaminants in the
testing well that interfered with the absorbance reading. Silk samples below 0.25 EU/mL
are in bold. Standard deviations were calculated using STDEV.P in Microsoft Excel.
Sample Type

Sample

Treatment

Results
(EU/mL)

Empty vial

B1

None

0.05 ± 0.00

Empty vial

B2

Autoclave x3

0.06 ± 0.00

Powder

B3

None

2.28 ± 0.02

Film

B4

Doping + Film

2.20 ± 0.01

Film

B5

Doping + Film

2.29 ± 0.01

Powder

B6

None

2.25 ± 0.01

Film

B7

Doping + Autoclave x3 + Film

0.185 ± 0

Film

B8

Doping + Autoclave x3 + Film

0.178 ± 0.01

Conclusion
Treating synthetic spider silk protein dopes with three consecutive autoclave cycles is
an effective method for reducing endotoxin levels. Autoclaving at the dope stage greatly
reduces endotoxin levels without destroying the protein-based materials or compromising
their mechanical properties, thus yielding the best combination of endotoxin level
reduction and mechanical properties in the final products. This combination will allow
synthetic spider silk research to progress to meaningful biocompatibility testing and,
eventually, clinical studies without the concern of endotoxin as a confounding factor.
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Methods
Preparation of Silk Samples
Most samples were made from goat-derived MaSp1 recombinant spider silk
protein. Silk proteins were extracted from goat milk and formed into either films or fibers
using the aqueous method described previously5,29. Briefly, silk proteins are removed
from defatted goat milk via tangential flow filtration, precipitation, washing, and
subsequent lyophilization. Silk protein solutions, or dopes, are then made by mixing the
dry protein with water and microwaving the mixture in a tightly sealed vial in 5-10 s
bursts to achieve a minimum temperature of 120 °C under high pressure to solvate. All
dopes used in this study were 5% (w/v) protein (150 mg protein in 3 mL water). Dopes
were then either poured onto PDMS molds to form films or spun into fibers using a
custom “wet spinning” spin line5,29.
Final samples were either a full film (30 mm x 6 mm x 50 µm), a six fiber bundle
(~25 cm length, ~30 µm diameter), or just protein powder. Powder samples were
prepared by vigorously vortexing 150 mg of protein powder in 3 mL of endotoxin-free
water for >5 min. The mixture was then centrifuged at 4,185 x g for 10 min, after which 1
mL of the supernatant was removed and stored for each sample. Samples were also taken
after doping following the same procedure used for the powders. For all sample sets,
control samples were taken prior to any treatments (including doping) and negative
controls (endotoxin-free water) were included.
Some samples were made from bacterially-derived MaSp2 recombinant spider
silk protein. Silk proteins were produced in Escherichia coli and subsequently extracted
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as previously described30. The proteins were then doped and samples were prepared as
described above.
As a note, the doping process is sufficient to sterilize the proteins for cell culture
work. Because of this, the doping process was tested for its effectiveness in destroying
endotoxin. It was shown that any reduction in endotoxin levels caused by microwaving
was insignificant (data not included), so other treatment methods were still required.

Endotoxin Removal/Destruction
Multiple methods of destroying endotoxins from samples were tried in this study:
dry heat, caustic washes, water washes, and autoclaving. All equipment used for
handling, storing, and preparing samples was depyrogenated via dry heat at 250 °C for at
least 30 min.
The dry heat treatment involved heating samples to 250 °C for at least 30 min or
180 °C for at least 3 hours. During heating, all samples were placed in a loosely covered
glass container. After heating, samples were covered and stored in a sterile PCR hood
until ready for use. Treated samples were only handled with endotoxin-free equipment, as
confirmed through the use of the preferred endotoxin detection kit used in these
experiments (data not included).
Caustic washes were performed with 1 M sodium hydroxide (NaOH). Treatments
were performed on dry spider silk samples by soaking in 40 mL of NaOH for 3 min. The
NaOH was then removed via centrifugation at 4,185 x g and the samples were rinsed with
endotoxin-free water three to five times, which was also removed via centrifugation.
Samples were then stored in a small amount of endotoxin-free water until testing.
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Autoclaving was performed on silk samples using a standard 20 min liquid cycle
(121 °C, 15 psig, 1 min purge). The cycle was repeated three times. The door was opened
for 1 min between each cycle to allow the autoclave pressure sensor to return to
atmospheric pressure before proceeding.
Protein powder was mixed with water and then autoclaved in loosely capped
bottles. After autoclaving, water was removed from powder samples via centrifugation at
4,185 x g and subsequent pipetting. Dopes were made as described above then transferred
to a clean vial that was loosely capped for autoclaving. After autoclaving, the protein
powder and dope samples were doped or redoped, respectively, before testing or casting
films.

Film Stretching
Some films were stretched before mechanical testing (Table 3-2). Stretching is a
common treatment performed on synthetic spider silk fibers and films to improve their
mechanical properties5,29. In this study, films were stretched in an 80:20
isopropanol:water bath to three times their original length using a stretching apparatus
developed by Tucker et al.5. Films were allowed to dry before being removed from the
stretching apparatus and tested. The stretching was not performed under endotoxin-free
conditions.

Resolubilization
To test whether it would be possible to make large stocks of endotoxin-free
protein powder for future use without the silk losing its mechanical properties, two
processes were tested on dopes that had been autoclaved three times: 1) the autoclaved
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dope was centrifuged at 4,185 x g, the supernatant was removed, and the protein pellet
was frozen; 2) the entire autoclaved dope was frozen. The frozen samples were then
lyophilized, after which the protein was resolubilized in water. Films were then made
using the standard procedure outlined above.

Endotoxin Level Analyses
The preferred kit to determine the endotoxin levels for these experiments was the
Pierce Limulus Amebocyte Lysate (LAL) Chromogenic Endotoxin Quantitation Kit
(Thermo Scientific Cat# 88282), which uses UV absorbance at 405-410 nm to determine
endotoxin concentration. This kit has a working detection range of 0.1-1.0 EU/mL.
Endotoxin levels above 1.0 EU/mL were extrapolated using an experimentally
determined standard curve equation.
Because testing a solid piece of silk material interfered with the UV absorbance
and confounded the endotoxin level readings, 1 mL of endotoxin-free water was added to
samples after endotoxin destruction treatments. Sample/water mixtures were vigorously
vortexed for >5 min to break apart the silk material and remove endotoxin from the silk
and the container into the water; 50 µL of the water was then used for endotoxin testing.
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CHAPTER 4
INVESTIGATION OF THE IN VIVO BIOCOMPATIBILITY OF GOAT-DERIVED
SPIDER SILK PROTEIN
Chapter Preface
The following chapter describes in vivo biocompatibility studies in which
materials made from goat-derived spider silk proteins were implanted into rats. Although
native spider silk is widely accepted as biocompatible, very little biocompatibility
research has been done on recombinant spider silk proteins and none has been reported
on goat-derived spider silk. Because the work presented in this chapter includes the first
in vivo studies of goat-derived spider silk, it is highly significant and impactful in the
synthetic spider silk research field.
Prior to the research described in this chapter, we performed some basic in vitro
work on goat-derived spider silk to show that multiple cell types (BHK, CHO, and PC12) could be grown on synthetic spider silk substrates (unpublished data), but these
studies were merely exploratory. Because the data produced from this previous work
have little scientific value beyond a basic assurance that cell viability is not affected when
growing cells on silk-based materials, the studies and results are not included.
The work presented in this chapter shows that, in its current form, goat-derived
spider silk is not biocompatible. A strong possibility for this unexpected negative result is
that the proteins, which are produced in goat milk, are contaminated with casein proteins.
Although the current protein purification method used to obtain the spider silk proteins
includes filtration and heating to remove casein, even trace amounts could prove
detrimental due to casein’s high immunogenicity. If this is the case, it is anticipated that
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proteins tagged with histidine and purified with affinity chromatography as described in
Chapter 2 of this dissertation will show a higher likelihood for biocompatibility.
It is important to note that the synthetic spider silk materials used in these studies
were susceptible to degradation by the rats’ immune system, which likely explains much
of the increased immunological response (e.g., increased numbers of macrophages at the
implantation site). While this is a concern, longer term implants may be completely
degraded and have little to no lasting effects on the host body. Although the studies
presented here are essentially preliminary work to be followed up with longer term
implantation studies using silk with a higher purity level, we feel that they provide a
crucial step in the direction of using goat-derived spider silk materials for biomedical
applications.
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Introduction
Native spider silk, particularly major ampullate (dragline) silk, has long been
known as a biocompatible material1,2. Dragline silk in particular has great potential in the
biomedical field because of its biocompatibility and impressive mechanical properties3.
Unfortunately, it is extremely difficult to obtain native spider silk in high quantities
because of the difficulties associated with farming spiders due to their cannibalistic and
territorial nature. To facilitate the use of spider silk in many different commercial
applications, particularly biomedical applications, synthetic spider silk proteins have been
created in multiple systems, including bacteria, silkworms, and goats4–8. Of these
systems, the most consistently large quantities of silk proteins are produced in goat milk.
Although native spider silk and some recombinant spider silk proteins (rSSps) are
known to be biocompatible1,2, no in vivo biocompatibility studies of goat-derived rSSps
have been reported to our knowledge. In order to determine the feasibility of using goatderived rSSp materials for medical applications, it is essential that the silk’s
biocompatibility be determined. Below, we describe three in vivo studies in rats aimed at
gathering preliminary data on the biocompatibility of two goat-derived spider silk
products: thin films and hydrogels. Rats were euthanized after 1, 2, 4, or 6 weeks and
tissue samples were collected to determine the localized immune response of the
implanted material. The findings from these studies establish a baseline for the current
biocompatibility level of goat-derived rSSps and highlight areas for improving that level
to facilitate the use of these protein-based materials for biomedical applications.
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Materials and Methods
Preparation of Implant Materials
Films
Silk films were composed of goat-derived Major Ampullate Spidroin 1 (MaSp1) –
one of the two proteins that compose dragline silk – as described previously9. Briefly, the
proteins were mixed in water to create a 5% (w/v) silk solution or dope. The dope was
then heated in 5 – 10 s bursts under pressure to at least 120 °C. The dope was treated for
endotoxin via triple autoclaving10, then heated again before being poured onto
polydimethylsiloxane (PDMS) molds that had been treated for endotoxin using dry heat
(250 °C for 30 min). Resultant films were approximately 15 mm x 6 mm x 50 µm.
Thin polytetrafluoroethylene (PTFE) pieces were used as controls (Grainger,
30FZ37). The PTFE pieces were cut to match the films’ surface area as closely as
possible (approximately 15 mm x 6 mm x 25 µm) and then treated for endotoxin by
either dry heating at 250 °C for 30 min or triple autoclaving. Pieces treated with both
methods were used as controls.
Hydrogels
Silk hydrogels were either a 50/50 blend of MaSp1 and MaSp2, or pure MaSp1,
depending on the study; hydrogel composition is noted for each study. Dopes were
created and treated similarly to the dopes used to create films, but with the silk
concentration being 20% (w/v) and the addition of 2% (v/v) propionic acid to aid
solubility at this relatively high concentration. After autoclaving and reheating, dopes
were cooled overnight in tightly sealed vials in a closed laminar flow hood. Hydrogel
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discs measuring 3 mm thick and 6 mm in diameter were punched out of the solidified
dope using metal punches that had been treated for endotoxin via dry heat (250 °C for 30
min). Hydrogels were placed in sterile petri dishes and left to soak in Dulbecco’s
phosphate buffered saline (DPBS) for 48-72 hours prior to implantation, with the DPBS
being replaced after 24 hours. The pH of the DPBS was tested to ensure the propionic
acid had leeched out to avoid a potential confounding factor.
Controls in the hydrogel study were made from Poly(ethylene Glycol) diacrylate
(referred to herein as PEG) due to its biocompatibility and low immunological
reponse11,12. 10% (w/v) PEG hydrogels were made in DPBS using PEG with an average
MW of 10 kDa (Laysan Bio Inc, ACRL-PEG-ACRL-10K-5g). Photoinitiator (2Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone) (Sigma-Adlrich, 410896) was
added to a final concentration of 0.25% (w/w), after which the mixture was vortexed
vigorously until no particles were visible (30-60 s). Following mixing, the solution was
exposed to UV light (365 nm) for 15 min to initiate crosslinking. PEG hydrogels were
triple autoclaved to ensure endotoxin destruction and sterility, then allowed to sit
overnight before being punched into implantable discs measuring approximately 3 mm
thick and 6 mm in diameter. Discs were soaked in DPBS for 48-72 hours prior to
implantation, with the DPBS being replaced after 24 hours.
Animal Studies
Wistar rats were obtained from Charles River Laboratories (Wilmington, MA).
The rats were acclimatized for approximately 1 week prior to surgical procedures. All
procedures were conducted in an AAALAC accredited Laboratory Animal Research
Center at Utah State University. All procedures received prior approval by Utah State
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University’s Institutional Animal Care and Use Committee. Animals were anesthetized
with isoflurane via inhalation. The dorsa of the animals were shaved and skin was
disinfected with chlorhexidine and 70% isopropyl alcohol. Four 1 cm incisions were
created approximately 2 cm apart on both sides of the back (8 incisions total),
approximately 2 cm from the midline (Figure 4-1). Subcutaneous pockets were created
using blunt dissection and implants were placed in the pockets. Following implantation,
incisions were closed using 3-0 polyglactin suture (Vicryl®, Ethicon J460H).
Buprenorphine (0.1 mg/kg) (PAR Pharmaceuticals) and enrofloxacin (5 mg/kg)
(Baytril®) were administered intramuscularly before returning rats to their home cages.
After the allotted time post-surgery, rats were euthanized via carbon dioxide
asphyxiation. Sutures were removed after euthanization in the case of the 1 and 2 week
groups or 14 days post-surgery in the case of the 4 and 6 week groups.

Figure 4-1. Graphical representation of incisions (red lines) and subcutaneous pockets
(gray boxes) made in rats for implantation studies. Numbers indicate sample number and
were assigned for ease of sample evaluation. Image is not to scale.
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Film Study
The films study was conducted on 6 rats. Films and surrounding tissue were
harvested 4 weeks post-implantation. The rats were shaved prior to tissue collection.
Tissue samples were fixed for ≥24 hours in formalin before being taken for
histopathological evaluation.
Hydrogel Study
The hydrogel study was conducted on 18 rats. Gels and surrounding tissue were
harvested from 6 rats at 1 week, 6 rats at 2 weeks, and 6 rats at 6 weeks. The rats were
shaved prior to tissue collection. Tissue samples were fixed for ≥24 hours in formalin
before being taken for histopathological evaluation.
Histopathological Evaluation
Fixed tissue samples were sliced to approximately 3 mm thick, 1 cm deep, and 1.5
cm long in preparation for embedding in paraffin. Samples were then evaluated to
produce a semi-quantitative score of local tissue response according to ISO 10993 Part-6
(2007)13, and Muhamed et al.14. In each histology session, the following parameters were
studied: number of inflammatory cells (neutrophils, plasma cells, lymphocytes, and
macrophages), number of foreign body giant cells (FBGCs), severity of necrosis, extent
of neovascularization, extent of fibrosis, and extent of fatty infiltration. The average
semi-quantitative score was then calculated as [(subtotal-I x 2) + subtotal-II], wherein
subtotal-I is the sum of scores for neutrophil, lymphocyte, plasma cell, macrophage, giant
cell, and severity of necrosis and subtotal-II is the sum of the scores for
neovascularization, fibrosis, and fatty infiltration. The difference of the score for the test
material from the reference material was then designated as the “irritancy score.”
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A simpler, less quantitative analysis based on work by Nyska et al.15, in which
results were graded from 1 to 4 based on inflammation present (lymphocytes, neutrophils,
macrophages) and fibrous capsule size, was also done: Grade I: slight reaction with a few
inflammatory cells; Grade II: clear inflammatory reaction with one or two giant cells;
Grade III: fibrous tissue with inflammatory cells, lymphocytes, and giant cells; and Grade
IV: granuloma with encapsulated implants and clear foreign-body reaction.
Silk Clean Up
For one of the hydrogel implantation studies, potential contaminates were
removed from goat-derived spider silk proteins using reverse phase chromatography
(RPC). Proteins were solubilized in 4 M Urea at a 3% (w/v) concentration. The protein
solutions were diluted to 2% (w/v) then run on an AKTA Avant with an XK 50 x 25
column with 200 ml of GE SOURCE 30RPC resin (GE Healthcare, 17-5120-02).
Proteins were eluted using acetonitrile (Sigma-Aldrich 34851-4L), 0.1% (v/v) Pierce®
Trifluoroacetic acid (ThermoFisher Scientific 28904) at a gradient of 0 – 50% over 10
column volumes. Fractions were collected at 45 mL intervals in 50 mL conical tubes
(VWR 37001-468). Acetonitrile was allowed to evaporate in a chemical fume hood
overnight before samples were concentrated by heating at 90 °C until samples had been
reduced to 25% of their starting volume, which took approximately 12 hours. HPLCgrade acetone (Pharmco-Aaper 32900HPLC) was then added at a 3:1 ratio
(acetone:sample); the mixture was shaken vigorously and then stored at -20 °C overnight
to facilitate protein precipitation. Samples were then centrifuged at 4 °C at 3200 x g for
30 min in a Beckman AllegraTM 6KR centrifuge. The supernatant was analyzed via
Western Blot to verify that all of the rSSp had been removed. The protein pellet was
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frozen and lyophilized. The presence of silk was verified via Western Blot analysis. This
silk protein is designated as RPC MaSp1 throughout this manuscript.
Western Blot
Western Blot analyses were conducted on RPC MaSp1 to determine which peaks
contained silk. A 1 mL sample of each fraction was concentrated to 20 µL and diluted 1:1
in SABU. SDS-PAGE gels were loaded with 20 µL of the concentrated fraction/SABU
solution and run at 110 V for 80 min. Gels were transferred to a nitrocellulose membrane
overnight at 35 mA in a wet transfer apparatus. Western Blots were performed on the
membranes with a custom made primary antibody produced in rabbits that targets the
native C-term of major ampullate spider silk proteins used at a 1:1000 dilution. A donkey
anti-rabbit Alkaline Phosphatase (AP) conjugated antibody (Rockland 611-705-127) was
used as the secondary antibody at a 1:5000 dilution. The membranes were developed in
1-StepTM NBT/BCIP Substrate Solution (ThermoFisher Scientific 34042) for imaging.
For the RPC MaSp1 implantation study, blood was drawn prior to surgery and
following euthanasia. Blood was allowed to sit for >30 min before being centrifuged at
2000 x g in a Beckman Coulter Microfuge®18 centrifuge. Serum was collected and
aliquoted then stored at -20 °C. Serum samples were used as the primary antibody at a
1:2000 dilution with a rabbit anti-rat IgG AP conjugated secondary antibody (SigmaAldrich A6066) to determine whether the silk implanted had instigated an immune
response, thus leading to the production of silk-specific antibodies in the rat. These
Western Blots were run following the same protocol described above.
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Results and Discussion
The first study conducted was the film implantation study. Upon visual
inspection, the tissue showed similar reactivity to both silk and PTFE implants. The
histopathology results initially only included the simpler grading scale (Table 4-1). Based
on these results, the response of spider silk films was determined to be comparable to that
of PTFE films, providing grounds to progress to a larger scale study. One concern with
using films again was that we could not determine the implant site of many of the
samples. In the case of the missing rSSp films, we suspect the films had been completely
resorbed into the body, making it difficult to find the sample implantation site when
excising the tissue. Consequently, it was determined that hydrogels would be a better
material to test, as they are larger and it was anticipated that they would be more stable
long-term under in vivo conditions.

Table 4-1. Average histology results from the film implantation study. Grading was on a
whole number scale of 1 to 4: Grade I: slight reaction with a few inflammatory cells;
Grade 2: clear inflammatory reaction with one or two giant cells; Grade 3: fibrous tissue
with inflammatory cells, lymphocytes, and giant cells; and Grade 4: granuloma with
encapsulated implants and clear foreign-body reaction. Standard deviations were
calculated using Microsoft Excel STDEV.P.
Sample Type
Autoclaved PTFE
Dry Heated PTFE
Silk

Inflammation (lymphocytes,
neutrophils, probably
macrophages)
2 ± 0.447
2 ± 0.433
2 ± 0.573

Fibrous
capsule

Grade

n

4 ± 0.4
3 ± 0.829
4 ± 0.442

3±0
3±0
3±0

10
4
15

Contrary to the results we anticipated to see for the hydrogel study based on the
results of the film study, it was very apparent when observing implant sites during
necropsies that the silk hydrogels were not comparable to the PEG hydrogel controls. The
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PEG gels were highly visible and the surrounding tissue did not show any obvious signs
of inflammation (redness, bleeding, swelling, etc.) at any time points except for 1 week.
Any inflammation at the 1 week time point was attributed to the incision, sutures, and
surgical procedure in general. The silk hydrogels were not readily visible due to a
blackish-red abscess surrounding each of the implants. Although the abscess surrounding
the silk was not as visible at 1 week as at other time points, it was present (Figure 4-2A),
especially when compared to the PEG tissue samples (Figure 4-2B). At 6 weeks the
encapsulation of the silk material was very apparent, while the PEG remained free of
encapsulation (Figure 4-2C). Histopathology results confirmed the visual inspection at
both week 1 and week 6 (Table 4-2) – inflammation and fibrosis were significantly
higher for silk samples. Although no pictures are available of samples at week 2,
histopathology results are presented in Table 4-2 for comparison. As can be seen, the
week 2 results are very similar to the week 1 results. None of the rats showed any signs
of systemic infection post-surgery and the tissue inflammation was localized to the
implant region.
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Figure 4-2. Tissue samples from rats implanted with silk and PEG hydrogels. A) Silk
implant at 1 week. B) PEG implant at 1 week. C) PEG (top) and silk (bottom) implants at
6 weeks. A ruler with 1 mm increments was included with each image for scale.

Table 4-2. Average histopathology results for hydrogel implant study. Scores were rated
from 1 to 4 in each category. Total score is equal to (Infl. Sub x2) + Fibro. Sub. Standard
deviations were calculated using Microsoft Excel STDEV.P. Low n values for 6 week
samples were due to the researchers only selecting a small sample group in light of the
obvious encapsulation visible.

Polymorphonuclear
Cells
Lymphocytes
Plasma Cells
Macrophages
Giant Cells
Severity of Necrosis
Infl. Sub
Neovascularization
Fibrosis
Fatty Infiltrate
Fibro. Sub
Total score
n

Silk
1 Week
4±0

PEG
1 Week
0 ± 0.484

Silk
2 Weeks
4±0

PEG
2 Weeks
1 ± 0.492

Silk
PEG
6 Weeks 6 Weeks
4±0
0±0

3 ± 0.2
1±0
3 ± 0.2
0 ± 0.498
4 ± 0.2
15 ± 0.64
3±0
4±0
0±0
7±0
37 ± 1.28
24

2±1
0 ± 0.276
2 ± 0.331
0 ± 0.611
0 ± 0.276
5 ± 1.26
1 ± 0.471
4 ± 0.599
0±0
5 ± 0.789
15 ± 2.67
24

2±0
1 ± 0.196
3±0
1 ± 0.528
4±0
15 ± 0.632
3 ± 0.196
4±0
0±0
7 ± 0.196
37 ± 1.28
24

1 ± 0.734
0±0
2 ± 0.287
0 ± 0.516
0±0
4 ± 1.22
2 ± 0.5
4±0
0±0
6 ± 0.5
14 ± 2.68
23

3±0
1±0
4±0
1±0
4±0
17 ± 0
3±0
4±0
0±0
7±0
41 ± 0
2

0±0
0±0
1±0
0 ± 0.471
0±0
1 ± 0.471
0±0
4 ± 0.471
0±0
4 ± 0.471
6 ± 0.471
3
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Following the hydrogel implantation study, more complex histology data for the
film study samples was requested (Table 4-3). These data showed that, although the
response due to silk and PTFE was indeed similar, the results had not actually been good.
Because native spider silk is biocompatible, it was determined that the immune response
was not actually due to the silk itself, but more likely due to contaminants present in the
synthetic spider silk, such as casein, a highly immunologic milk protein. In order to
investigate this, we sought to purify the silk using Reverse Phase Chromatography
(RPC).

Table 4-3. Average histopathology results for film implants. Scores were rated from 1 to
4 in each category. Total score is equal to (Infl. Sub Score x2) + Fibro. Sub Score.
Standard deviations were calculated using Microsoft Excel STDEV.P. Low n values for
PTFE were due to tissue samples being harvested from incorrect implant locations.
Silk
Polymorphonuclear Cells 1 ± 0.696
Lymphocytes
2 ± 0.848
Plasma Cells
0 ± 0.456
Macrophages
2 ± 0.478
Giant Cells
0 ± 0.322
Severity of Necrosis
1 ± 0.832
Infl. Sub Score
7 ± 3.047
Neovascularization
2 ± 0.730
Fibrosis
4±0
Fatty Infiltrate
0±0
Fibro. Sub Score
6 ± 0.730
Total score
20 ± 6.608
n
17

Dry Heated PTFE
1 ± 0.471
1±0
0±0
2 ± 0.373
0±0
0±0
4 ± 0.687
1 ± 0.943
4 ± 0.373
0±0
5 ± 1.067
14 ± 1.893
6

Autoclaved PTFE
1 ± 0.40
1 ± 0.748
0±0
2±0
0±0
0 ± 0.4
4 ± 0.748
1 ± 0.4
4±0
0±0
5 ± 0.4
14 ± 1.744
5

Spider silk dopes containing 2% spider silk in 4 M Urea were submitted to RPC
as described in Materials and Methods. Peaks containing spider silk (as shown by
Western Blot analysis) eluted in acetonitrile were collected. After acetone precipitation,
centrifugation, and lyophilization, the silk protein (designated herein as RPC MaSp1) was
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doped in nanopure water and treated for endotoxins via triple autoclaving. The protein
was then redoped and hydrogels were made from it under sterile conditions. The RPC
MaSp1 hydrogels, which were noticeably softer than non-RPC MaSp1 hydrogels, were
implanted into 2 rats. A third rat was implanted with non-RPC MaSp1 as a positive
control. PEG was again used as the negative control.
Two weeks post-implantation necropsies were performed on all 3 rats. After just 2
weeks, many of the RPC MaSp1 gels had been resorbed, either partially or completely.
This was likely due to the decreased stiffness of the RPC MaSp1 gels, which made it
much easier for the gels to be broken into very small pieces via mechanical forces, such
as handling with forceps or pressure on the implantation site post-surgery. These small
gel pieces were more accessible to the macrophages, making them easier to digest. A
capsule was still visible around remaining silk implants, although it was less pronounced
than those in the original hydrogel study and (visibly) the RPC MaSp1 implants were less
encapsulated than the non-RPC MaSp1 hydrogels. Visual inspection (Figure 4-3) and
histopathology results (Table 4-4) indicated that the inflammatory response was similar
to the results seen in the first hydrogel study at 2 weeks (Table 4-2).
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Figure 4-3. Tissue samples from rats implanted with silk and PEG hydrogels. Samples
were collected 2 weeks post-implantation. A) RPC MaSp1 hydrogel; the gel is hard to see
because it was broken in pieces during implantation – arrows have been added to indicate
the 3 largest pieces of the gel. B) Silk hydrogel implant. C) PEG hydrogel implant. A
ruler with 1 mm increments was included with each image for scale.

Table 4-4. Average histopathology results for hydrogel implant study. Scores were rated
from 1 to 4 in each category. Total score = (Infl. Sub Score x2) + Fibro. Sub Score.
Standard deviations were calculated using Microsoft Excel STDEV.P.
RPC MaSp1
Polymorphonuclear Cells 1 ± 0.661
Lymphocytes
2 ± 0.331
Plasma Cells
0 ± 0.331
Macrophages
4±0
Giant Cells
3 ± 0.696
Severity of Necrosis
0 ± 0.484
Infl. Sub Score
10 ± 1.479
Neovascularization
2 ± 0.331
Fibrosis
2 ± 1.936
Fatty Infiltrate
0±0
Fibro. Sub Score
3 ± 2.058
Total score
23 ± 4.885
n
8

Silk
3±0
2±0
0±0
3±0
1±0
3±0
12 ± 0
3±0
4±0
0±0
7±0
31 ± 0
4

PEG
1 ± 0.64
1 ± 0.64
0±0
2±0
0 ± 0.64
0 ± 0.276
5 ± 1.323
1 ± 0.493
4±0
0±0
5 ± 0.493
14 ± 2.9
12

To determine whether the rats in the RPC MaSp1 study were creating antibodies
to the spider silk, plasma was taken from the rats for use as a primary antibody against
MaSp1 silk in a Western Blot analysis, with an anti-rat IgG secondary antibody. The
band present in Figure 4-4 indicates that the rats were producing Immunoglobulin G in
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response to the silk implant, implying that the silk hydrogel had elicited an immune
response in the rats.

Figure 4-4. Western Blot analysis of rSSp using rat blood as the primary antibody. Left:
blood drawn prior to implantation (pre-surgery). Right: blood drawn during necropsies (2
weeks post-surgery). Black arrow indicates 64 kDa where the MaSp1 band is present on
the right, but missing on the left. The molecular weight standard was the Bio-Rad Dual
Color Precision Plus ProteinTM Standard.
Because of the genetic similarity between synthetic spider silk and native spider
silk, it is more likely a contaminate present, possibly acting as an adjuvant, in the goatderived transgenic spider silk proteins that is causing an immune response than the silk
itself. Further clean-up of the silk and the material production conditions should lead to a
decreased immune response. It is also likely that the immune response seen in the RPC
MaSp1 hydrogel study was due to the rats’ bodies responding as they would to nearly any
foreign material: breaking it down to remove it from their system. We suspect that a
much longer (≥6 weeks) time point would result in no visible immune response. If this is
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the case, an early immune response is not only expected, but could actually be beneficial,
as it would facilitate removal of the silk protein structure over time, which would be ideal
for applications such as cell scaffolds and drug delivery.
Conclusion
At their current stage, goat-derived synthetic spider silk proteins are not
sufficiently biocompatible due to contaminants in the proteins. Given the nature of the
farm environment the proteins come from and, more significantly, the environment the
proteins are purified in, as well as the purification process itself, these results are not all
together unexpected. To further elucidate whether synthetic spider silk can be used as an
effective biomaterial, more extensive work will need to be done. Further research into
purifying and cleaning the silk proteins through RPC and other methods is still needed. It
is highly possible that, over longer periods of time, the silk (especially the RPC MaSp1)
will be completely degraded by the host, unlike the PTFE and PEG controls used in these
experiments. This biodegradability would partially negate many of the concerns relating
to the immediate inflammatory response the silk creates, especially because the response
is localized, not systemic. Regardless, further work to investigate potential contaminates
in the silk should provide much needed information about the negative response seen in
these studies.
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CHAPTER 5
ENGINEERING SIGNIFICANCE
One of the key concepts in biological engineering is to harness the power of
existing biological systems to develop innovative systems that either mimic or improve
on naturally occurring ones, particularly with the goal of creating marketable products
and/or improving human lives. A core principle in any field of engineering that readily
applies to biological engineering is to design, build, and test. Both of these concepts were
employed during the work described in this dissertation. As was discussed throughout,
spider silk proteins have great potential for use in producing marketable materials,
particularly biomaterials for medical applications, but the current quantities and purity
level of spider silk are not sufficient for these to come to fruition.
In producing a new goat cell line to be used to create improved “spider goats,”
multiple iterations of designing, building, and testing were necessary. It was initially
proposed to use targeted gene editing to replace a native goat milk protein gene with a
spider silk protein gene such that it would be produced using the goat’s native regulatory
controls. Multiple gene editing systems were designed to target regions of the goat
genome, but upon building and testing these systems, it was ultimately decided that,
while it may be possible to incorporate silk in this way, the time, resources, and potential
for failure (if the gene knockout proved fatal or the goats were unable to produce any
milk), would likely not be compensated by the theoretical improvement of the silk
proteins quality and quantity. Consequently, an effective and practical random integration
method was designed and tested to facilitate the creation of new goats. As described in
Chapter 2, this method was an effective way to create a goat cell line for use in creating
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goats to produce silk proteins that can be purified more efficiently and more completely.
This will allow for an overall increase in protein yield and purity, thus enabling research
on spider silk as a biomaterial to move forward more effectively.
Although current recombinant spider silk proteins are being used to produce and
evaluate a variety of materials, their biocompatibility had not been tested. Also, there was
no established method for dealing with the issue of endotoxin contamination in the
proteins that was likely to occur, especially in the bacterially-derived proteins. Lack of
biocompatibility information and an endotoxin removal procedure were two major
roadblocks to using these silk-based biomaterials for medical applications. In determining
the best protocol for decreasing the endotoxins present in goat-derived silk to an FDA
acceptable level, multiple methods were evaluated for their effectiveness as well as their
impact on the mechanical properties of the silk materials. After building, testing, and
redesigning protocols based on general techniques for endotoxin removal, a method was
established to destroy endotoxins in spider silk proteins (regardless of the production
source – goats or bacteria) without compromising the mechanical properties of the silkbased materials made from those proteins.
Following the endotoxin preparatory work, the biocompatibility tests described in
Chapter 4 could be developed. The procedure for these tests was redesigned multiple
times to determine the best materials to use to efficiently test the silk proteins. Initially,
thin films were used, but it was determined that hydrogels would be a better testing
material, as the films degraded quickly, making it difficult to find the implantation site.
The control materials also had to be evaluated following initial studies to find a better
material to match the hydrogels. Results from the film and hydrogel studies provided
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feedback that could be used to redesign the silk purification process in an attempt to
decrease the inflammatory response caused by silk-based materials. The results of these
tests also re-emphasize the importance of creating new goats to produce proteins that can
be purified more completely, as mentioned above. Through these in vivo studies, we have
established a baseline for the biocompatibility of goat-derived silk proteins. This baseline
gives us essential information regarding the future work needed to improve our
recombinant silk protein purification process. For this future work, we suggest that
characterization of the impurities present in our silk protein be completed to elucidate
areas of improvement for the silk purification process. We have also established a
standardized protocol for effectively testing silk-based materials regardless of its source
(goats, plants, bacteria, or silkworms) that can be used for future biocompatibility
evaluation.
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CHAPTER 6
SUMMARY AND CONCLUSIONS
Recombinant spider silk proteins (rSSps) produced in transgenic hosts,
particularly goats, hold great promise for use in the biomedical field. Increasing the
amount and purity of these rSSps are two critical achievements needed to move proteinbased materials from laboratory studies to clinic applications. The new “spider goat” cell
line described in Chapter 2 will allow for production of more goat-derived proteins that
can be purified more completely. Even with this improvement, endotoxin contamination
is still a concern for these proteins as well as proteins acquired from other sources. The
method established to remove endotoxins in rSSps described in Chapter 3, significantly
increases the likelihood of creating medical-grade proteins.
Although the biocompatibility tests described in Chapter 4 did not yield the
positive results we anticipated, the data obtained are valuable in that they have
established a biocompatibility baseline for goat-derived rSSps. This baseline creates a
starting point for future biocompatibility work – characterizing the contaminants present
in the spider silk proteins and then determining the best method for removing those
contaminants. This could be accomplished through the use of mass spectrometry, which
could verify whether the immunological protein casein is present in our protein mixtures
and provide information about whether or not other non-silk proteins are present.
More important than the biocompatibility baseline established through this work
is the establishment of a standardized method for testing the biocompatibility of rSSps
(whether from goats or another source). By having a standardized protocol, future studies
can now be evaluated without the need of excessive background work and pilot studies
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that could require the unnecessary use of more animal lives than needed. Although
further work will be needed to improve the purity level of rSSps, the work completed for
this dissertation has helped to establish a roadmap for that future work, moving goatderived spider silk closer to biomedical applications.
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APPENDIX A
CHAPTER 3 SUPPLEMENTARY INFORMATION
Table A1-1. Endotoxin levels of goat-derived synthetic spider silk protein treated with
various endotoxin destruction techniques. Although all protein came from the same stock,
horizontal lines are used to separate different sample batches that were treated and tested
at different times. The R2 of the standard curve was ≥ 0.989 for all experiments. Silk
samples below 0.25 EU/mL are in bold. Sample 9 had n=2 due to a negative absorbance
on one of the sample replicates that was excluded from the average. Sample 15 was made
on untreated PDMS. Standard deviations were calculated using STDEV.P in Microsoft
Excel.
Sample Type

Sample

Treatment

Endotoxin Level
(EU/mL)

n

Powder

1

None

5.02 ± 0.07

2

Film

2

NaOH rinse + H20 rinse

2.08 ± 0.11

2

Film

3

NaOH rinse + H20 rinse

4.05 ± 0.42

2

Powder

4

Doping

5.20 ± 0.24

3

Powder

5

Doping + Autoclave x3

0.307 ± 0.10

3

Film

6

Doping + Autoclave x3 + Film

0.249 ± 0.08

3

Powder

7

Doping

1.73 ± 0.10

3

Powder

8

Doping + Autoclave x3

0.063 ± 0.01

3

Film

9

Doping + Autoclave x3 + Film

0.103 ± 0.01

2

Powder

10

Doping

1.99 ± 0.05

3

Powder

11

Doping + Autoclave x3

0.115 ± 0.00

3

Film

12

Doping + Autoclave x3 + Film

0.123 ± 0.06

3

Powder

13

Doping

1.79 ± 0.13

3

Powder

14

Doping + Autoclave x3

0.098 ± 0.01

3

Film

15

Doping + Autoclave x3 + Film

1.62 ± 0.03

3
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Powder

16

Doping

2.23 ± 0.02

2

Film

17

Doping + Film

1.17 ± 0.02

2

Film

18

Doping + Film

0.446 ± 0.02

2

Powder

19

Doping

2.28 ± 0.01

2

Powder

20

Doping + Autoclave x3

0.136 ± 0.01

2

Film

21

Doping + Autoclave x3 + Film

0.202 ± 0.02

2

Film

22

Doping + Autoclave x3 + Film

0.214 ± 0.00

2
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Figure 1-2 – Elsevier License
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